In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About Gandara 0:19 • The interview 1:02 • Can you tell me a little more about what you are working on now? 1:25 • How did you get engaged with the community in Hawaii? 6:30 • What do you think is going to happen with ctDNA moving forward? 8:29 • Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy? 11:42 • How did you get into the ctDNA space? 15:06 • How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health? 18:28 • Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do? 23:17 • What are some of your predictions as to what will happen in oncology care over the next ten to twenty years? 29:00 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30 • How to contact Gandara 38:47 • Thanks for listening 39:10 David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development.

We'd love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email [email protected].

Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine.